Replies to post #244558 on Biotech Values

[DewDiligence]

MGNX receives $60M milestone from PRVB for FDA approval of Tzield:

https://www.globenewswire.com/news-release/2022/11/17/2558767/0/en/MacroGenics-Earns-60-Million-Milestone-with-U-S-FDA-Approval-of-Teplizumab.html

[DewDiligence]

PRVB/SNY price Tzield at $193K per treatment course:

https://endpts.com/provention-gets-fda-nod-on-drug-to-delay-type-i-diabetes-kicking-off-us-launch-with-sanofi/

[DewDiligence]

Tzield is a major breakthrough—maybe (NYT):

https://www.nytimes.com/2022/11/18/health/fda-type-1-diabetes-delay.html

There’s a dilemma vis-à-vis the right time to start therapy. If started too early—i.e. when the patient has detectable autoimmune antibodies but does not yet have damage to the pancreas—Tzield may not work. OTOH, if therapy is started too late—when damage to the pancreas has already occurred—the clinical benefit is reduced to some degree.

A further problem is that screening for autoimmune antibodies capable of causing T1D is rarely done unless a patient has close relatives already diagnosed with T1D.

[DewDiligence]

SNY acquires PRVB for $25.00 cash—a 273%(!) premium to Friday’s closing price:

https://finance.yahoo.com/news/press-release-sanofi-acquire-provention-060000049.html

The nominal deal value is $2.9B.

SNY and PRVB already had a US co-marketing deal for Tzield, PRVB’s novel drug to delay the onset of T1D (#msg-170131014).